Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis

Circulation

Volumn 131, Issue 7, 2015, Pages 656-668

  Musumeci, Lucia ^a   Kuijpers, Marijke J ^f   Gilio, Karen ^f   Hego, Alexandre ^a   Théâtre, Emilie ^a,b   Maurissen, Lisbeth ^a,f   Vandereyken, Maud ^a   Diogo, Catia V ^a   Lecut, Christelle ^a   Guilmain, William ^a   Bobkova, Ekaterina V ^g   Eble, Johannes A ^i,j   Dahl, Russell ^g   Drion, Pierre ^c   Rascon, Justin ^g   Mostofi, Yalda ^g   Yuan, Hongbin ^g   Sergienko, Eduard ^g   Chung, Thomas D Y ^g   Thiry, Marc ^d   Senis, Yotis ^k   Moutschen, Michel ^a   Mustelin, Tomas ^d   Lancellotti, Patrizio ^a,e   Heemskerk, Johan W M ^f   Tautz, Lutz ^h,i   Oury, Cécile ^a   Rahmouni, Souad ^a   more..

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GIGA Animal Facility (B23)   (Belgium)

^d GIGA Neurosciences   (Belgium)

^e Department of Cardiology   (Belgium)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^h National Cancer Center Research Institute   (United States)

ⁱ BURNHAM INSTITUTE   (United States)

^j UNIVERSITY OF MÜNSTER   (Germany)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Antagonists and inhibitors; Blood platelets; Signal transduction; Thrombosis

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; COLLAGEN; CONVULXIN; DUAL SPECIFICITY PHOSPHATASE 3; ENZYME INHIBITOR; GLYCOPROTEIN VI; MITOGEN ACTIVATED PROTEIN KINASE; MLS 0049585; MLS 0103602; PADGEM PROTEIN; PHOSPHOLIPASE C GAMMA2; UNCLASSIFIED DRUG; DUSP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; B LYMPHOCYTE; BLEEDING TIME; BLOOD CLOTTING; CALCIUM TRANSPORT; CELL LYSATE; COLORIMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; LUNG EMBOLISM; MOUSE; NONHUMAN; NORMAL HUMAN; PLATELET AGGREGATION ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE VOLUME; THROMBOEMBOLISM; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; KNOCKOUT MOUSE; MALE; PHYSIOLOGY; THROMBOSIS;

ANIMALS; CELLS, CULTURED; DUAL SPECIFICITY PHOSPHATASE 3; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET ACTIVATION; PULMONARY EMBOLISM; THROMBOSIS;

EID: 84923774213     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.010186     Document Type: Article

References (43)

1. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010; 9: 154-169. doi: 10.1038/nrd2957.
2. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost. 2005; 3: 1752-1762. doi: 10.1111/j.1538-7836.2005.01429.x.
3. Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain JR, Jin LL, Harris IS, Mori J, Mak TW, Senis YA, Östman A, Moran MF, Neel BG. Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome." Cell. 2011; 146: 826-840. doi: 10.1016/j. cell.2011.07.020.
4. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T. Protein tyrosine phosphatases in the human genome. Cell. 2004; 117: 699-711. doi: 10.1016/j.cell.2004.05.018.
5. Tautz L, Critton DA, Grotegut S. Protein tyrosine phosphatases: structure, function, and implication in human disease. Methods Mol Biol. 2013; 1053: 179-221. doi: 10.1007/978-1-62703-562-0-13.
6. Ishibashi T, Bottaro DP, Chan A, Miki T, Aaronson SA. Expression cloning of a human dual-specificity phosphatase. Proc Natl Acad Sci U S A. 1992; 89: 12170-12174.
7. Cerignoli F, Rahmouni S, Ronai Z, Mustelin T. Regulation of MAP kinases by the VHR dual-specific phosphatase: implications for cell growth and differentiation. Cell Cycle. 2006; 5: 2210-2215.
8. Wang JY, Yeh CL, Chou HC, Yang CH, Fu YN, Chen YT, Cheng HW, Huang CY, Liu HP, Huang SF, Chen YR. Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer. J Biol Chem. 2011; 286: 10177-10184. doi: 10.1074/jbc. M110.163295.
9. Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, Zhu C, Louisdit-Sully C, Moutschen M, Jiang W, Mustelin T. Loss of the VHR dualspecific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol. 2006; 8: 524-531. doi: 10.1038/ncb1398.
10. Henkens R, Delvenne P, Arafa M, Moutschen M, Zeddou M, Tautz L, Boniver J, Mustelin T, Rahmouni S. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer. 2008; 8: 147. doi: 10.1186/1471-2407-8-147.
11. Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, Saatcioglu F. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res. 2008; 68: 9255-9264. doi: 10.1158/0008-5472.CAN-08-1224.
12. Amand M, Erpicum C, Bajou K, Cerignoli F, Blacher S, Martin M, Dequiedt F, Drion P, Singh P, Zurashvili T, Vandereyken M, Musumeci L, Mustelin T, Moutschen M, Gilles C, Noel A, Rahmouni S. DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase. Mol Cancer. 2014; 13: 108. doi: 10.1186/1476-4598-13-108.
13. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood. 2002; 100: 2499-2505. doi: 10.1182/blood-2002-03-0812.
14. Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, Hoylaerts MF. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood. 2003; 101: 3969-3976. doi: 10.1182/blood-2002-10-3215.
15. Gilio K, van Kruchten R, Braun A, Berna-Erro A, Feijge MA, Stegner D, van der Meijden PE, Kuijpers MJ, Varga-Szabo D, Heemskerk JW, Nieswandt B. Roles of platelet STIM1 and Orai1 in glycoprotein VI-and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem. 2010; 285: 23629-23638. doi: 10.1074/jbc.M110.108696.
16. Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, van Zandvoort MA, Rosing J, Bock PE, Watson SP, Heemskerk JW. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 2007; 27: 2484-2490. doi: 10.1161/ATVBAHA.107.151100.
17. Heemskerk JW, Sage SO. Calcium signalling in platelets and other cells. Platelets. 1994; 5: 295-316. doi: 10.3109/09537109409006439.
18. Kuijpers MJ, Munnix IC, Cosemans JM, Vlijmen BV, Reutelingsperger CP, Egbrink MO, Heemskerk JW. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation. 2008; 15: 269-282. doi: 10.1080/10739680701653517.
19. Senis YA, Tomlinson MG, Ellison S, Mazharian A, Lim J, Zhao Y, Kornerup KN, Auger JM, Thomas SG, Dhanjal T, Kalia N, Zhu JW, Weiss A, Watson SP. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood. 2009; 113: 4942-4954. doi: 10.1182/blood-2008-08-174318.
20. Watson SP, Asazuma N, Atkinson B, Berlanga O, Best D, Bobe R, Jarvis G, Marshall S, Snell D, Stafford M, Tulasne D, Wilde J, Wonerow P, Frampton J. The role of ITAM-and ITIM-coupled receptors in platelet activation by collagen. Thromb Haemost. 2001; 86: 276-288.
21. Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med. 1998; 188: 267-276.
22. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, Fässler R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J. 2001; 20: 2120-2130. doi: 10.1093/ emboj/20.9.2120.
23. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, O'Reilly LA, Henley KJ, Ono A, Hsiao S, Willcox A, Roberts AW, Huang DC, Salem HH, Kile BT, Jackson SP. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009; 114: 663-666. doi: 10.1182/blood-2009-01-200345.
24. Bobkova EV, Liu WH, Colayco S, Rascon J, Vasile S, Gasior C, Critton DA, Chan X, Dahl R, Su Y, Sergienko E, Chung TD, Mustelin T, Page R, Tautz L. Inhibition of the hematopoietic protein tyrosine phosphatase by phenoxyacetic acids. ACS Med Chem Lett. 2011; 2: 113-118. doi: 10.1021/ ml100103p.
25. Siljander P, Farndale RW, Feijge MA, Comfurius P, Kos S, Bevers EM, Heemskerk JW. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol. 2001; 21: 618-627.
26. May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble J, Elvers M, Nieswandt B. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood. 2009; 114: 3464-3472. doi: 10.1182/ blood-2009-05-222273.
27. Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, Finney BA, Vögtle T, Remer K, Braun A, Bösl M, Watson SP, Nieswandt B. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol. 2013; 33: 926-934. doi: 10.1161/ ATVBAHA.112.300672.
28. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood. 2003; 102: 1701-1707. doi: 10.1182/ blood-2003-03-0717.
29. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006; 107: 3902-3906. doi: 10.1182/ blood-2005-09-3687.
30. Konishi H, Katoh Y, Takaya N, Kashiwakura Y, Itoh S, Ra C, Daida H. Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury. Circulation. 2002; 105: 912-916.
31. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, Shin Y, Hirashima M, Ozaki Y. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/ lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 2010; 285: 24494-24507. doi: 10.1074/ jbc.M110.130575.
32. Massberg S, Gawaz M, Grüner S, Schulte V, Konrad I, Zohlnhöfer D, Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. 2003; 197: 41-49.
33. Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, Matsumoto Y, Yoshitake M, Kambayashi J, Tandon NN. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res. 2006; 118: 371-380. doi: 10.1016/j. thromres.2005.08.001.
34. Navarro-Núñez L, Langan SA, Nash GB, Watson SP. The physiological and pathophysiological roles of platelet CLEC-2. Thromb Haemost. 2013; 109: 991-998. doi: 10.1160/TH13-01-0060.
35. Séverin S, Pollitt AY, Navarro-Nuñez L, Nash CA, Mourão-Sá D, Eble JA, Senis YA, Watson SP. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem. 2011; 286: 4107-4116. doi: 10.1074/jbc. M110.167502.
36. Loyau S, Dumont B, Ollivier V, Boulaftali Y, Feldman L, Ajzenberg N, Jandrot-Perrus M. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol. 2012; 32: 778-785. doi: 10.1161/ ATVBAHA.111.241067.
37. Usui T, Kojima S, Kidokoro S, Ueda K, Osada H, Sodeoka M. Design and synthesis of a dimeric derivative of RK-682 with increased inhibitory activity against VHR, a dual-specificity ERK phosphatase: implications for the molecular mechanism of the inhibition. Chem Biol. 2001; 8: 1209-1220.
38. Ueda K, Usui T, Nakayama H, Ueki M, Takio K, Ubukata M, Osada H. 4-Isoavenaciolide covalently binds and inhibits VHR, a dual-specificity phosphatase. FEBS Lett. 2002; 525: 48-52.
39. Hirai G, Tsuchiya A, Koyama Y, Otani Y, Oonuma K, Dodo K, Simizu S, Osada H, Sodeoka M. Development of a Vaccinia H1-related (VHR) phosphatase inhibitor with a nonacidic phosphate-mimicking core structure. ChemMedChem. 2011; 6: 617-622. doi: 10.1002/cmdc.201100107.
40. Park H, Jung SK, Jeong DG, Ryu SE, Kim SJ. Discovery of VHR phosphatase inhibitors with micromolar activity based on structure-based virtual screening. ChemMedChem. 2008; 3: 877-880. doi: 10.1002/cmdc.200700348.
41. Shi Z, Tabassum S, Jiang W, Zhang J, Mathur S, Wu J, Shi Y. Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects. Chembiochem. 2007; 8: 2092-2099. doi: 10.1002/cbic.200700397.
42. Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, Tautz L. Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem. 2009; 52: 6716-6723. doi: 10.1021/ jm901016k.
43. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46: 3-26.